PARP-1 siRNA (h) from Santa Cruz Biotechnology, Inc.

Product Specs
ItemPARP-1 siRNA (h)
CompanySanta Cruz Biotechnology, Inc.
Price $293.00Supplier Page View Company Product Page
Catalog Numbersc-29437
Gene Namepoly (ADP-ribose) polymerase 1
Quantity10 µM
Specieshuman
NCBI Full Gene Namepoly(ADP-ribose) polymerase 1
NCBI Gene AliasesADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1, PARS, PPOL, Poly-PARP, pADPRT-1
TypesiRNA/dsRNA

Add to Compare List

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Targeting fatty acid synthase to overcome PARP inhibitor resistance and to create an artificial synthetic lethality for triple-negative breast cancerGenes & DiseasesAugust 20, 2025Sophia Josephraj, Chao J. Wang, Qingbin Cui, Zizheng Dong, Jing-Yuan Liu, Jian-Ting Zhang(Invitrogen). For stable knockdown, the cells were transfected with pSilencer2.1-U6/shFASN13 or shPARP1 (#sc-29437, Santa Cruz, California, USA) plasmids using Lipofectamine™ 3000 (Fisher Scientific), according to the

(2) Total Glucosides of Paeony Ameliorate Myocardial Injury in Chronic Heart Failure Rats by Suppressing PARP-1Journal of Cardiovascular Translational ResearchApril 1, 2024Wenjuan Wei, Caiyan Li, Baoyong Zhang, Deyun Huang, Zheming Li, Jiaer GaoUSA. Transfection H9C2 cells (1 × 105 cells/mL) were transfected with poly(ADP-ribose)polymerase 1 (PARP-1) siRNA (sc-29437, Santa Cruz Biotechnology, CA, USA) or a negative control in Opti-MEM Medium (31985062, Invitrogen,

(3) Expression of NORAD correlates with breast cancer aggressiveness and protects breast cancer cells from chemotherapyMolecular therapy. Nucleic acidsSeptember 12, 2023Alves-Vale C, Capela AM, Tavares-Marcos C, Domingues-Silva B, Pereira B, Santos F, Gomes CP, Espadas G, Vitorino R, Sabidó E, et al.same as in Tichon et al.12 KD efficiency was assessed by qRT-PCR. siRNAs used for PARP1 (Santa Cruz, sc-29437) and CDK1 (Thermo Fisher Scientific, AM16704 103821) were used at 25 nM. KD efficiency was assessed

(4) Poly(N-vinylpyrrolidone)-block-Poly(dimethylsiloxane)-block-Poly(N-vinylpyrrolidone) Triblock Copolymer Polymersomes for Delivery of PARP1 siRNA to Breast CancersACS applied bio materialsApril 18, 2022Yang Y, Kozlovskaya V, Zhang Z, Xing C, Zaharias S, Dolmat M, Qian S, Zhang J, Warram JM, Yang ES, et al.

(5) Niraparib-induced STAT3 inhibition increases its antitumor effectsFrontiers in oncologyJanuary 1, 2022Zhao Q, Kohut A, Li YJ, Martincuks A, Austria T, Zhang C, Santiago NL, Borrero RM, Phan XT, Melstrom L, et al.

(6) Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCAJournal of medicinal chemistrySeptember 9, 2021Wang C, Qu L, Li S, Yin F, Ji L, Peng W, Luo H, Lu D, Liu X, Chen X, et al.

(7) PARP Traps Rescue the Pro-Inflammatory Response of Human Macrophages in the In Vitro Model of LPS-Induced TolerancePharmaceuticals (Basel, Switzerland)February 22, 2021Pietrzak J, Gronkowska K, Robaszkiewicz A.

(8) Long non-coding RNA H19 regulates proliferation and doxorubicin resistance in MCF-7 cells by targeting PARP1BioengineeredDecember 1, 2020Wang Y, Zhou P, Li P, Yang F, Gao XQ.

(9) Role of Poly [ADP-ribose] Polymerase 1 in Activating the Kirsten ras (KRAS) Gene in Response to Oxidative StressInternational journal of molecular sciencesAugust 28, 2020Cinque G, Ferino A, Pedersen EB, Xodo LE.

(10) PARP1 Co-Regulates EP300-BRG1-Dependent Transcription of Genes Involved in Breast Cancer Cell Proliferation and DNA RepairCancersOctober 11, 2019Sobczak M, Pitt AR, Spickett CM, Robaszkiewicz A.Ligase I (sc-271678), anti-CDK4 (sc-23896), anti-NEIL3 (sc-393703), anti-pADPr (sc-56198), siPARP1 (sc-29437), and gallotannin were purchased from Santa Cruz Biotechnology (AMX, Lodz, Poland). ChIP grade antibodies:

(11) PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervixOncotargetJuly 2, 2019Mann M, Kumar S, Sharma A, Chauhan SS, Bhatla N, Kumar S, Bakhshi S, Gupta R, Kumar L.

(12) Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor SensitivityCell reportsJune 18, 2019Marcar L, Bardhan K, Gheorghiu L, Dinkelborg P, Pfäffle H, Liu Q, Wang M, Piotrowska Z, Sequist LV, Borgmann K, et al.River,N/A Oligonucleotides,Oligonucleotides,Oligonucleotides "siRNA against PARP-1, validated",Santa Cruz,sc-29437 "siRNA against XRCC1, validated",Ambion,121593 "siRNA against RAC1, validated",Sigma Aldrich,EHU075591 Software

(13) NR4A Nuclear Receptors Target Poly-ADP-Ribosylated DNA-PKcs Protein to Promote DNA RepairCell reportsFebruary 19, 2019Munnur D, Somers J, Skalka G, Weston R, Jukes-Jones R, Bhogadia M, Dominguez C, Cain K, Ahel I, Malewicz M.

(14) Remifentanil Protects against Lipopolysaccharide-Induced Inflammation through PARP-1/NF-κB Signaling PathwayMediators of inflammationJanuary 1, 2019Zhang JN, Ma Y, Wei XY, Liu KY, Wang H, Han H, Cui Y, Zhang MX, Qin WD.before stimulation. 2.2. siRNA Transfection. To inhibit PARP-1 expression, HAECs were transfected with PARP-1 siRNA (sc-29437, Santa Cruz Biotechnology, CA, USA) or negative control in Opti-MEM Medium (Invitrogen, CA, USA) by

(15) Nuclear cGAS suppresses DNA repair and promotes tumorigenesisNatureNovember 1, 2018Liu H, Zhang H, Wu X, Ma D, Wu J, Wang L, Jiang Y, Fei Y, Zhu C, Tan R, et al.

(16) Trastuzumab-Resistant HER2⁺ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) InhibitionMolecular cancer therapeuticsMay 1, 2018Wielgos ME, Zhang Z, Rajbhandari R, Cooper TS, Zeng L, Forero A, Esteva FJ, Osborne CK, Schiff R, LoBuglio AF, et al.Santa Cruz Biotechnology and contains three to five siRNA pools specifically targeting the PARP-1 gene (sc-29437; Santa Cruz Biotechnology). Another PARP-1 siRNA from Sigma-Aldrich(#NM_001618, SASI_Hs01_00159524)

(17) PARP1 facilitates EP300 recruitment to the promoters of the subset of RBL2-dependent genesBiochimica et biophysica acta. Gene regulatory mechanismsDecember 4, 2017Robaszkiewicz A, Wiśnik E, Regdon Z, Chmielewska K, Virág L.

(18) Downregulation of PARP1 transcription by promoter-associated E2F4-RBL2-HDAC1-BRM complex contributes to repression of pluripotency stem cell factors in human monocytesScientific reportsAugust 25, 2017Wiśnik E, Płoszaj T, Robaszkiewicz A.(PMA), WB antibodies: anti-PARP1 (sc-7150), anti-PU.1 (sc-22805), anti-β-tubulin (sc-5546), siPARP1 (sc-29437), siPU.1 (sc-36330) were from Santa Cruz Biotechnology (AMX, Lodz, Poland), TRI Reagent, iAgo2 (aurintricarboxylic

(19) Sunitinib induces genomic instability of renal carcinoma cells through affecting the interaction of LC3-II and PARP-1Cell death & diseaseAugust 10, 2017Yan S, Liu L, Ren F, Gao Q, Xu S, Hou B, Wang Y, Jiang X, Che Y.specific for human MAP LC3β (sc-43390), Ulk1 (sc-44182), p62 (sc-25575), Rad51 (sc-36361) and PARP-1 (sc-29437) were purchased from Santa Cruz Biotechnology (Dallas, TX, USA), along with the control siRNA (sc-37007).

(20) Poly (ADP-ribose) polymerase-1 inhibition decreases proliferation through G2/M arrest in esophageal squamous cell carcinomaOncology lettersAugust 1, 2017Yamamoto M, Yamasaki M, Tsukao Y, Tanaka K, Miyazaki Y, Makino T, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, et al.

Be the First to Write a Review!

PARP-1 siRNA (h)

PARP-1 siRNA (h) from Santa Cruz Biotechnology, Inc.

Description

Santa Cruz Biotechnology, Inc.

Citations (42)

Reviews

PARP-1 siRNA (h) from Santa Cruz Biotechnology, Inc.

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map